The therapeutic effects of FGF19 on obesity and T2DM are due to the activation of the FGFR1/β-Klotho complex, which determines weight loss and lowers plasma glucose levels and insulin resistance [135,136]. This evidence concerns the gene FGF19 and type 2 diabetes mellitus.